Gly-β-MCA

Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders[1].

Product Specifications

CAS Number

[66225-78-3]

Product Name Alternative

Y-39983 (free base)

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; FXR

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Gly-_beta_-MCA.html

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)

Smiles

C[C@@H]([C@@]1([H])CC[C@@]2([H])[C@@]3([H])[C@]([C@]4(CC[C@@H](O)C[C@H]4[C@H](O)[C@@H]3O)C)([H])CC[C@]12C)CCC(NCC(O)=O)=O

Molecular Formula

C26H43NO6

Molecular Weight

465.62

Precautions

H302, H315, H319, H335

References & Citations

[1]Jiang C, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015 Dec 15;6:10166.